Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-center and Single-arm Clinical Study of INK Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia

NCT06702098 is registered in ClinicalTrials.gov with Guangzhou Ruixin Biotechnological Co., LTD as lead sponsor.

NCT NCT06702098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06702098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-center and Single-arm Clinical Study of INK Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia
Lead sponsor
Guangzhou Ruixin Biotechnological Co., LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 25, 2024
Completion date
November 24, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml)